Knight Therapeutics Inc.

TSX:GUD.TO

Drug Manufacturers - Specialty & Generic

Healthcare
$11.56 +0.75%

+$0.07 today

Market cap
$1.14B
Beta
0.07
P/E (TTM)
164.6
EPS (TTM)
$0.06
52W Low $5.66High $9.59

Volume 0.04M

Average 0.10M

GUD.TO Deferred Income Tax

The difference between tax expense recognized and tax actually paid in cash during the period.

Knight Therapeutics Inc.TSX: GUD.TO

Deferred Income Tax · Q1 FY2026 · quarter ended Mar 2026

Deferred income tax turns positive

Q1 FY2026 deferred income tax was CA$830K, compared with -CA$3.12M a year earlier. Trailing-twelve-month deferred income tax was CA$138K. Over 3 fiscal years it compounded at -39.4% a year.

Context

  • Deferred income tax amounted to 0.8% of revenue in FY2025, unchanged from a year earlier.
  • Deferred income tax grew in size in 1 of the last 3 fiscal years.

What to watch

Whether quarterly deferred income tax holds near CA$830K or moves back toward the trailing-twelve-month quarterly average of CA$34.5K.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
CA$830K-68.0% QoQ
Last fiscal yearDec 2025
-CA$3.81M+17.5% YoY
LTMMar 2026
CA$138K+106.6% YoY
Deferred Income Tax past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+126.6%——
1 year+17.5%——
3-year CAGR-39.4%——
5-year CAGR——
10-year CAGR——

Deferred Income Tax history

CAD · from the cash flow

Latest · FY2025
(3.81M) CAD
Year-over-year change
-17.5%

Deferred Income Tax vs competitors

How GUD.TO compares with its peers on the latest reported figures

  • Peers report in different currencies, so deferred income tax is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +106.6% is the highest of 7, against a peer median of -43.2%.
  • Deferred income tax amounts to 0.0% of revenue for GUD.TO, versus a peer median of 0.4%.
GUD.TO Competitors
Deferred Income Tax for GUD.TO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
OGI.TOOrganiGram Holdings Inc.LTM Mar 2026CA$13.66M CAD-45646.7%—5.0%
CPH.TOCipher Pharmaceuticals Inc.LTM Mar 2026$10.64M USD+43.2%-10.2%20.9%
VHI.TOVitalhub Corp.LTM Mar 2026CA$2.93M CAD——2.5%
TSND.TOTerrAscend Corp.LTM Mar 2026$1.1M USD-140.2%-77.4%0.4%
KSI.TOKneat.com, Inc.LTM Mar 2026CA$225.4K CAD+12.1%—0.3%
GUD.TOKnight Therapeutics Inc.LTM Mar 2026CA$138K CAD+106.6%-39.4%0.0%
WEED.TOCanopy Growth CorporationLTM Mar 2026CA$107.47K CAD-98.5%—0.0%
ACB.TOAurora Cannabis Inc.LTM Mar 2026CA$55K CAD+101.7%—0.0%
Peer median (excluding GUD.TO) —-43.2%-43.8%0.4%

Competitors are the stored peer set for GUD.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

CAD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income15.68M(29.89M)(16.84M)4.33M(5.37M)
Depreciation & Amortization47.92M62.62M50.4M53.11M56.57M
Deferred Income Tax(7.64M)(17.13M)(9.13M)(3.24M)(3.81M)
Stock-Based Compensation3.05M1.89M2.33M1.86M8.11M
Change in Working Capital627K(9.99M)(28.01M)(19.62M)1.89M
Accounts Receivables8.59M(26.42M)5.58M(10.29M)(26.53M)
Inventory(17.19M)(11.43M)698K(5.91M)(17.82M)
Accounts Payables11.46M30.6M(21.63M)632K42.11M
Other Working Capital(2.23M)(2.74M)(12.66M)(4.06M)4.14M
Other Non-Cash Items(15.01M)32.98M37.19M(154K)12.91M
Operating Cash Flow44.62M40.48M35.94M36.28M70.3M
Capital Expenditures(224.18M)(25.82M)(9.96M)(31.47M)(1.91M)
Acquisitions (Net)(220.35M)000(110.05M)
Purchases of Investments(64.32M)(185.47M)(334.16M)(162.57M)(70.39M)
Sales of Investments180.54M150.54M345.47M196.12M112.43M
Other Investing Activities223.04M(2.33M)18.99M(14.12M)17.6M
Investing Cash Flow(105.28M)(63.08M)29.34M16.96M(84.11M)
Debt Repayment(14.19M)31.49M(18.02M)(18.05M)23.19M
Common Stock Issued0000511K
Common Stock Repurchased(64.42M)(30.07M)(53.48M)(8.87M)(6.35M)
Dividends Paid00000
Other Financing Activities297K(4.18M)(9.5M)(6.62M)(4.34M)
Financing Cash Flow(78.31M)1.76M(81M)(33.54M)13.01M
Effect of Forex Changes(4.66M)6.55M2.8M1.64M(2.86M)
Net Change in Cash(143.63M)(14.28M)(12.92M)21.35M(3.66M)
Free Cash Flow(179.57M)14.67M25.98M4.81M68.4M

Knight Therapeutics Inc.

TSX:GUD.TO

Intrinsic Alpha fair value

Locked

Current Price

$11.56

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.